JP2007504242A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504242A5
JP2007504242A5 JP2006525453A JP2006525453A JP2007504242A5 JP 2007504242 A5 JP2007504242 A5 JP 2007504242A5 JP 2006525453 A JP2006525453 A JP 2006525453A JP 2006525453 A JP2006525453 A JP 2006525453A JP 2007504242 A5 JP2007504242 A5 JP 2007504242A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006525453A
Other versions
JP2007504242A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/028660 external-priority patent/WO2005023314A1/en
Publication of JP2007504242A publication Critical patent/JP2007504242A/ja
Publication of JP2007504242A5 publication Critical patent/JP2007504242A5/ja
Pending legal-status Critical Current

Links

JP2006525453A 2003-09-03 2004-09-02 マトリックスメタロプロテイナーゼ基質含有化合物およびそれらの使用法 Pending JP2007504242A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49996003P 2003-09-03 2003-09-03
US49996603P 2003-09-03 2003-09-03
PCT/US2004/028660 WO2005023314A1 (en) 2003-09-03 2004-09-02 Compounds containing matrix metalloproteinase substrates and methods of their use

Publications (2)

Publication Number Publication Date
JP2007504242A JP2007504242A (ja) 2007-03-01
JP2007504242A5 true JP2007504242A5 (ja) 2007-04-12

Family

ID=34278690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006525453A Pending JP2007504242A (ja) 2003-09-03 2004-09-02 マトリックスメタロプロテイナーゼ基質含有化合物およびそれらの使用法

Country Status (6)

Country Link
US (1) US20050106100A1 (ja)
EP (1) EP1691845A4 (ja)
JP (1) JP2007504242A (ja)
AU (1) AU2004270200A1 (ja)
CA (1) CA2537771A1 (ja)
WO (1) WO2005023314A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
CA2644694C (en) * 2006-03-10 2014-05-13 Sangeeta N. Bhatia Triggered self-assembly conjugates and nanosystems
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP3495822B1 (en) 2006-04-04 2023-12-20 Novilux, LLC Method for assessing acute myocardial infarction based on highly sensitive analysis of cardiac troponin
GB0707034D0 (en) * 2007-04-12 2007-05-23 St Andrews The Compounds
US20110165606A1 (en) * 2007-06-15 2011-07-07 Tutturen Astrid E V Methods for modifying, isolating, detecting, visualizing, and quantifying citrullinated and/or homocitrullinated peptides, polypeptides and proteins
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
US20100221180A1 (en) * 2007-08-31 2010-09-02 Yanming Wang In vivo imaging of myelination
BRPI0907612A2 (pt) 2008-01-08 2015-07-21 Lantheus Medical Imaging Inc Conjugados de n-coxiamida como agentes de imageamento
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
CA2742265C (en) * 2008-10-29 2014-07-15 Bg Medicine, Inc. Galectin-3 immunoassay
CN106995495A (zh) * 2009-01-12 2017-08-01 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
JP5861223B2 (ja) * 2009-02-23 2016-02-16 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. プロタンパク質およびその使用方法
JP5678045B2 (ja) 2009-06-08 2015-02-25 シンギュレックス・インコーポレイテッド 高感度バイオマーカーパネル
US8877157B2 (en) 2009-07-08 2014-11-04 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
MX2012002371A (es) * 2009-08-25 2012-06-08 Bg Medicine Inc Galectina-3 y terapia de resincronizacion cardiaca.
EP2775906B1 (en) 2011-11-11 2019-07-03 Yale University Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
RU2607041C2 (ru) * 2015-05-29 2017-01-10 Общество с ограниченной ответственностью "Научно-производственная фирма ДНК-Технология" Способ определения степени гноетечения на пародонте по уровню мРНК гена интерлейкина-8 (IL-8) человека
EP3579821A1 (en) * 2017-02-10 2019-12-18 Boston Scientific Scimed, Inc. Vascular ulcer treatment
MX2020010715A (es) 2018-04-10 2021-01-08 Sanofi Aventis Deutschland Sintesis de lixisenatida con taponamiento.
IN202021002695A (ja) * 2020-01-21 2021-07-23
EP4247785A1 (en) * 2020-11-19 2023-09-27 Novartis AG Synthesis of prostate specific membrane antigen (psma) ligands

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859777A (en) * 1981-07-01 1989-08-22 Eastman Kodak Company Terpyridine chelating agents
US4452774A (en) * 1982-04-30 1984-06-05 President And Fellows Of Harvard College Isonitrile radionuclide complexes for labelling and imaging agents
WO1987002893A1 (en) * 1985-11-18 1987-05-21 Board Of Regents, The University Of Texas System Polychelating agents for image and spectral enhancement (and spectral shift)
CA1305160C (en) * 1985-12-23 1992-07-14 Paul Louis Bergstein Ether isonitriles and radiolabeled complexes thereof
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
US5252317A (en) * 1986-11-10 1993-10-12 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
US5567411A (en) * 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
US5064956A (en) * 1987-06-24 1991-11-12 The Dow Chemical Company Process for preparing mono-n-alkylated polyazamacrocycles
US5087440A (en) * 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
GB8923843D0 (en) * 1989-10-23 1989-12-13 Salutar Inc Compounds
GB9006977D0 (en) * 1990-03-28 1990-05-23 Nycomed As Compositions
ATE187340T1 (de) * 1991-03-27 1999-12-15 Nycomed Salutar Inc Kontrastmittel
GB9209641D0 (en) * 1992-05-02 1992-06-17 Johnson Matthey Plc Improvements in radiolabelling
US5760191A (en) * 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
US5744120A (en) * 1993-03-30 1998-04-28 The Dupont Merick Pharmaceutical Company Ternary radiopharmaceutical complexes
US5750088A (en) * 1993-03-30 1998-05-12 The Dupont Merck Pharmaceutical Company Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
HU222574B1 (hu) * 1993-03-31 2003-08-28 Mallinckrodt Medical Inc. Redukálószerként foszfinokat tartalmazó radioaktív gyógyászati készítmények és az ezeket tartalmazó készletek
US5417959A (en) * 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
SE515621C2 (sv) * 1995-05-08 2001-09-10 Ericsson Telefon Ab L M Förfarande vid lägesbestämning
US5801228A (en) * 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
IT1275571B (it) * 1995-07-19 1997-08-07 Consiglio Nazionale Ricerche Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori
ES2217408T3 (es) * 1996-04-01 2004-11-01 Epix Medical, Inc. Agentes diagnosticos de contraste para formacion de imagenes bioactivados.
US5804161A (en) * 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
DE19717904A1 (de) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
US6083486A (en) * 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
US5980863A (en) * 1998-11-02 1999-11-09 Eagle Vision Pharmaceutical Corporation Manganese compositions and methods for MRI
US6254852B1 (en) * 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20030004141A1 (en) * 2001-03-08 2003-01-02 Brown David L. Medical devices, compositions and methods for treating vulnerable plaque

Similar Documents

Publication Publication Date Title
BE2024C508I2 (ja)
BE2022C549I2 (ja)
BE2024C511I2 (ja)
BE2020C513I2 (ja)
BE2020C517I2 (ja)
BE2019C540I2 (ja)
BE2019C548I2 (ja)
BE2018C045I2 (ja)
BE2017C027I2 (ja)
BE2017C023I2 (ja)
BE2016C067I2 (ja)
BE2016C014I2 (ja)
BE2015C041I2 (ja)
BE2015C038I2 (ja)
BE2015C066I2 (ja)
BE2015C014I2 (ja)
BE2014C071I2 (ja)
BE2014C064I2 (ja)
BE2014C063I2 (ja)
BE2019C535I2 (ja)
BE2014C010I2 (ja)
BE2013C071I2 (ja)
BE2015C065I2 (ja)
BE2013C021I2 (ja)
BE2012C025I2 (ja)